{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:08Z","timestamp":1793346428934,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The human operator is acknowledged as the greatest potential source of contamination in aseptic processing. To avoid contamination, barrier systems have progressively reduced the amount of human intervention in the critical zone. This study extends the trajectory of enhanced patient safety through the elimination of human intervention in aseptic filling. Eight companies that are users of closed robotic workcells have aggregated their usage data from 2018 to 2021. The study analyzes the critical design elements and performance of the Cytiva SA25 Aseptic Filling Workcell. The SA25 is a standardized, fully closed robotic system for aseptic filling of vials, syringes, and cartridges that eliminates operator intervention in the critical zone. The standardized design means that the system is not modified to suit a particular application and the same environmental monitoring strategy can be used across different installations. The SA25 provides significantly increased sterility assurance when producing sterile injectables. Users have observed non-viable particle levels well within ISO 5\/Grade A air requirements, with extremely low probabilities of entering a dosage container. There have been zero cases of microbial growth in more than 250 media fills and good manufacturing practice (GMP) batches. Across all dosage formats and sizes, the aseptic process is repeatable, with more than 99.3% of units meeting acceptance criteria. These data demonstrate that eliminating risk through design is successful in the SA25, with an improved aseptic process in comparison to filling systems using Restricted Access Barrier Systems (RABS) or isolators with glove ports. One of the contributing companies to this article achieved an industry first. The U.S. FDA-approved commercial production of their biologic drugs without the requirement for routine viable\u00a0environmental monitoring (EM), requiring viable EM only during process simulations. Based on the data presented and planned future research, new regulatory consideration should be made for closed robotic workcells to ensure that regulations meant for previous technologies with different risk profiles are not inappropriately applied.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-022-02360-3","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T17:02:34Z","timestamp":1659546154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Environmental Monitoring for Closed Robotic Workcells Used in Aseptic Processing: Data to Support Advanced Environmental Monitoring Strategies"],"prefix":"10.1208","volume":"23","author":[{"given":"Joseph","family":"McCall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonita","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Gadient","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Kasireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adara","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadd","family":"Putnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ine","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"4","key":"2360_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5731\/pdajpst.2011.00765","volume":"65","author":"T Sandle","year":"2011","unstructured":"Sandle T. A review of cleanroom microflora: types, trends, and patterns. PDA J Pharm Sci Technol. 2011 Jul 1;65(4):392\u2013403. https:\/\/doi.org\/10.5731\/pdajpst.2011.00765.","journal-title":"PDA J Pharm Sci Technol"},{"issue":"3","key":"2360_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0026-265x(92)90093-I","volume":"45","author":"S Vidali","year":"1992","unstructured":"Vidali S. Human contamination control in a clean room. Microchem J. 1992 Jun;45(3):336\u201342. https:\/\/doi.org\/10.1016\/0026-265x(92)90093-I.","journal-title":"Microchem J"},{"key":"2360_CR3","unstructured":"Sandle T. The development of cleanrooms: an historical review\u2013Part 2\u2013 The path towards international harmonisation. Editor\u2019s welcome. 2017:28."},{"issue":"5","key":"2360_CR4","first-page":"244","volume":"49","author":"J Agalloco","year":"1995","unstructured":"Agalloco J. Opportunities and obstacles in the implementation of barrier technology. PDA J Pharm Sci Technol. 1995 Sep 1;49(5):244\u20138.","journal-title":"PDA J Pharm Sci Technol"},{"key":"2360_CR5","unstructured":"U.S. Food and Drug Administration. Guidance for industry: sterile drug products produced by aseptic processing \u2013 current good manufacturing practice. FDA; 2004."},{"key":"2360_CR6","unstructured":"European Commission. Annex 1: manufacture of sterile medicinal products. EC; 2020 Draft."},{"key":"2360_CR7","unstructured":"United States Pharmacopeial Convention. USP general chapter <797>\u00a0Pharmaceutical compounding \u2013 Sterile preparations. USP; 2008."},{"issue":"4","key":"2360_CR8","first-page":"69","volume":"35","author":"J Agalloco","year":"2011","unstructured":"Agalloco J, Akers J. Revisiting interventions in aseptic processing. Pharm Technol. 2011 Apr 1;35(4):69\u201372.","journal-title":"Pharm Technol"},{"issue":"1","key":"2360_CR9","first-page":"3","volume":"43","author":"H Avallone","year":"1989","unstructured":"Avallone H. Current regulatory issues regarding parenteral inspections. J Parenter Sci Technol. 1989;43(1):3\u20137.","journal-title":"J Parenter Sci Technol"},{"issue":"7","key":"2360_CR10","first-page":"60","volume":"30","author":"J Agalloco","year":"2006","unstructured":"Agalloco J, Akers J. The simplified Akers-Agalloco method for aseptic processing risk analysis. Pharm Technol. 2006 Jul 1;30(7):60\u201376.","journal-title":"Pharm Technol"},{"issue":"41","key":"2360_CR11","first-page":"32","volume":"2","author":"JP Agalloco","year":"2017","unstructured":"Agalloco JP, Akers J. A revised aseptic risk assessment and mitigation methodology. Pharm Technol. 2017 Nov;2(41):32\u20139.","journal-title":"Pharm Technol"},{"key":"2360_CR12","unstructured":"Whyte W, Agricola K. Comparison of the loss of macroparticles and MCPs in cleanrooms by surface deposition and mechanical ventilation. Clean Air and Containment Review. 2018 Jul\/Aug;35:4\u201310."},{"key":"2360_CR13","unstructured":"Hughes P. Expedited programs: phase appropriate regulatory expectations for microbial control and sterility assurance. 2020. https:\/\/www.casss.org\/docs\/default-source\/cmc-strategy-forum-north-america\/2020-cmc-na-speaker-presentations\/speaker-presentation-hughes-patricia-cder-fda-2020.pdf?sfvrsn=298ed85e_4. Accessed 25 Mar 2021."},{"key":"2360_CR14","unstructured":"International Organization for Standardization. ISO 11137\u20132:2012. Sterilization of health care products \u2013 Radiation \u2013 Part 2: Establishing the sterilization dose. ISO; 2012."},{"key":"2360_CR15","unstructured":"International Organization for Standardization. ISO 11137\u20131:2006. Sterilization of health care products \u2013 Radiation \u2013 Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices. ISO; 2006."}],"updated-by":[{"DOI":"10.1208\/s12249-022-02398-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02360-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T21:05:47Z","timestamp":1661893547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02360-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02360-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12249-022-02398-3","URL":"https:\/\/doi.org\/10.1208\/s12249-022-02398-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB is an employee of Cytiva. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"215"}}